Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (483)	6/18/2004 4:05:11 PM
From: rkrw	of 496

I think midazolam (versed) is generic but not 100% sure. You should try emailing glfd IR. Can't remember her name, but if she's still there, she's a very good IR. OT: cgtk, I bt a small amount recently, but need to do more dd as well. A hugely binary stock. Phase III's hit statistical significance, I think it could be a $500M+ product. It's more of a device ala stents and with hard data, no reason not to be broadly adopted. If it flops, they become an early stage antisense company, maybe sell down to a few bucks a share. Outside of E2F they're extremely early and as far as I know have yet to figure out how to deliver the decoys. That's the easy part of E2F, no delivery issues, just stick it in the solution and mixer with the veins. I don't see any middle ground outcome, either a big bio success or a debacle. Founders are ex-Cor Therapeutics and Genentech, get it? :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next